Literature DB >> 21212839

The von Hippel-Lindau Tumor Suppressor Protein Is Destabilized by Src: Implications for Tumor Angiogenesis and Progression.

Mary T-H Chou1, Josephine Anthony, Jeffrey D Bjorge, Donald J Fujita.   

Abstract

The von Hippel-Lindau tumor suppressor protein (VHL), when mutated and inactivated, has been associated with renal and CNS cancer development. VHL normally plays an important role in targeting for degradation of the HIF-1α (hypoxia inducible factor-1α) transcription factor, a primary positive regulator of vascular endothelial growth factor (VEGF) production. In this report we demonstrate that VHL destabilization can be induced by Src kinase and may be involved in other cancers, including breast cancer. We have found that elevated Src can trigger a drastic reduction in VHL stability even under normoxic conditions, through phosphorylation of VHL tyrosine residue 185, leading to ubiquitination and proteasome-mediated degradation of VHL. The Src-induced degradation of VHL protein leads to increased HIF-1α levels and transcriptional activity and increased VEGF production. In this manner, Src regulation of VHL protein stability may play an important role in promoting VEGF expression, tumor angiogenesis, and cancer progression.

Entities:  

Year:  2010        PMID: 21212839      PMCID: PMC3014987          DOI: 10.1177/1947601910366719

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  45 in total

1.  E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis.

Authors:  Cho-Rok Jung; Kyung-Sun Hwang; Jinsang Yoo; Won-Kyung Cho; Jin-Man Kim; Woo Ho Kim; Dong-Soo Im
Journal:  Nat Med       Date:  2006-07-02       Impact factor: 53.440

Review 2.  Molecular mechanisms of tumor angiogenesis and tumor progression.

Authors:  U Cavallaro; G Christofori
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

3.  Catalytic specificity of protein-tyrosine kinases is critical for selective signalling.

Authors:  Z Songyang; K L Carraway; M J Eck; S C Harrison; R A Feldman; M Mohammadi; J Schlessinger; S R Hubbard; D P Smith; C Eng
Journal:  Nature       Date:  1995-02-09       Impact factor: 49.962

4.  Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase.

Authors:  R Y Fleming; L M Ellis; N U Parikh; W Liu; C A Staley; G E Gallick
Journal:  Surgery       Date:  1997-08       Impact factor: 3.982

Review 5.  The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors.

Authors:  G Neufeld; O Kessler; Z Vadasz; Z Gluzman-Poltorak
Journal:  Surg Oncol Clin N Am       Date:  2001-04       Impact factor: 3.495

6.  Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.

Authors:  B Zbar; T Kishida; F Chen; L Schmidt; E R Maher; F M Richards; P A Crossey; A R Webster; N A Affara; M A Ferguson-Smith; H Brauch; D Glavac; H P Neumann; S Tisherman; J J Mulvihill; D J Gross; T Shuin; J Whaley; B Seizinger; N Kley; S Olschwang; C Boisson; S Richard; C H Lips; M Lerman
Journal:  Hum Mutat       Date:  1996       Impact factor: 4.878

7.  Activating SRC mutation in a subset of advanced human colon cancers.

Authors:  R B Irby; W Mao; D Coppola; J Kang; J M Loubeau; W Trudeau; R Karl; D J Fujita; R Jove; T J Yeatman
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

8.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation.

Authors:  D Mukhopadhyay; L Tsiokas; X M Zhou; D Foster; J S Brugge; V P Sukhatme
Journal:  Nature       Date:  1995-06-15       Impact factor: 49.962

Review 9.  Molecular basis of the VHL hereditary cancer syndrome.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

Review 10.  Genotype-phenotype correlations in von Hippel-Lindau disease.

Authors:  H P Neumann; B U Bender
Journal:  J Intern Med       Date:  1998-06       Impact factor: 8.989

View more
  12 in total

1.  Metabotropic NMDA receptor signaling couples Src family kinases to pannexin-1 during excitotoxicity.

Authors:  Nicholas L Weilinger; Alexander W Lohman; Brooke D Rakai; Evelyn M M Ma; Jennifer Bialecki; Valentyna Maslieieva; Travis Rilea; Mischa V Bandet; Nathan T Ikuta; Lucas Scott; Michael A Colicos; G Campbell Teskey; Ian R Winship; Roger J Thompson
Journal:  Nat Neurosci       Date:  2016-02-08       Impact factor: 24.884

2.  Increased expression of the von Hippel-Lindau gene in the implantation site of human tubal pregnancy.

Authors:  Jian-Ying Xu; Wei-Jie Zhu; Huan Jiang
Journal:  Mol Cell Biochem       Date:  2012-06-20       Impact factor: 3.396

3.  Glucocorticoids promote Von Hippel Lindau degradation and Hif-1α stabilization.

Authors:  Andrea Vettori; David Greenald; Garrick K Wilson; Margherita Peron; Nicola Facchinello; Eleanor Markham; Mathavan Sinnakaruppan; Laura C Matthews; Jane A McKeating; Francesco Argenton; Fredericus J M van Eeden
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-29       Impact factor: 11.205

4.  BC-box protein domain-related mechanism for VHL protein degradation.

Authors:  Maria Elena Pozzebon; Archana Varadaraj; Domenico Mattoscio; Ellis G Jaffray; Claudia Miccolo; Viviana Galimberti; Massimo Tommasino; Ronald T Hay; Susanna Chiocca
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

5.  Regulation of KLF4 by posttranslational modification circuitry in endocrine resistance.

Authors:  Zhuan Zhou; Xinxin Song; Junlong Jack Chi; David R Gius; Yi Huang; Massimo Cristofanilli; Yong Wan
Journal:  Cell Signal       Date:  2020-02-19       Impact factor: 4.315

Review 6.  Control of vascular smooth muscle function by Src-family kinases and reactive oxygen species in health and disease.

Authors:  Charles E MacKay; Greg A Knock
Journal:  J Physiol       Date:  2014-12-01       Impact factor: 5.182

7.  Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line.

Authors:  Jeffrey D Bjorge; Andy S Pang; Melanie Funnell; Ke Yun Chen; Roman Diaz; Anthony M Magliocco; Donald J Fujita
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

Review 8.  Targeting tyrosine kinases and autophagy in prostate cancer.

Authors:  Hsing-Jien Kung
Journal:  Horm Cancer       Date:  2010-12-02       Impact factor: 3.869

9.  KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer.

Authors:  Jung-Jin Park; Yeung Bae Jin; Yoon-Jin Lee; Jae-Seon Lee; Yun-Sil Lee; Young-Gyu Ko; Minyoung Lee
Journal:  BMC Cancer       Date:  2012-03-06       Impact factor: 4.430

10.  Src regulates the activity of the ING1 tumor suppressor.

Authors:  Lisa Yu; Satbir Thakur; Rebecca Yy Leong-Quong; Keiko Suzuki; Andy Pang; Jeffrey D Bjorge; Karl Riabowol; Donald J Fujita
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.